Hepion Pharmaceuticals, Inc. 8-KCurrent Reports (8-K / ad hoc)

Market for Equity / Stockholders

Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On August 19, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) approved the appointment of James Liddy as a director of the Company, effective immediately. There are no arrangements or understandings between the new director and any other person pursuant to which he was selected as a director, and there are no transactions involving the Company and the new director that the Company would be required to report pursuant to Item 404(a) of Regulation S-K. Field: Page; Sequence: 2; Options: NewSection; Value: 2 Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence Field: /Page SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 20, 2026 Hepion Pharmaceuticals, Inc. By: /s/ Gary Stetz Gary Stetz Interim Chief Executive Officer Field: Page; Sequence: 3; Options: Last Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence Field: /Page Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjd0KwjAMhZ9g7xB6La5WHLJLh4o4RcYQb4uLUtyakda/R/It7TbEEAjJOV+OECOxppWpkeG0KHIosWlr7REKvCCjPWNwZJttCmEWeDXOs7a+X39gRoHBwCTjmQ733vkwDqsU5DxWMlYJSJXKKRx2Iur0jOzFVGi90TVoW8GBqWWDXvN7+FDqF1lq3n3SEdkZsilMxnKQP6DkRMGeHvpJfHOQ55mIRn1FYs10b4Nr+fJoOxKWNTYhzg30v6MvyzFKWw==